Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 252

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Antibody-Drug Conjugates for the Treatment of Non–Hodgkin's Lymphoma: Target and Linker-Drug Selection

Polson, Andrew G., Calemine-Fenaux, Jill, Chan, Pamela, Chang, Wesley, Christensen, Erin, Clark, Suzanna, de Sauvage, Frederic J., Eaton, Dan, Elkins, Kristi, Elliott, J. Michael, Frantz, Gretchen, Fuji, Reina N., Gray, Alane, Harden, Kristin, Ingle, Gladys S., Kljavin, Noelyn M., Koeppen, Hartmut, Nelson, Christopher, Prabhu, Saileta, Raab, Helga, Ross, Sarajane, Stephan, Jean-Philippe, Scales, Suzie J., Spencer, Susan D., Vandlen, Richard, Wranik, Bernd, Yu, Shang-Fan, Zheng, Bing, Ebens, Allen·2009·Cancer Research

Abstract

Antibody-drug conjugates (ADC), potent cytotoxic drugs covalently linked to antibodies via chemical linkers, provide a means to increase the effectiveness of chemotherapy by targeting the drug to neoplastic cells while reducing side effects. Here, we systematically examine the potential targets and linker-drug combinations that could provide an optimal ADC for the treatment for non–Hodgkin's lymphoma. We identified seven antigens (CD19, CD20, CD21, CD22, CD72, CD79b, and CD180) for potential treatment of non–Hodgkin's lymphoma with ADCs. ADCs with cleavable linkers mediated in vivo efficacy via all these targets; ADCs with uncleavable linkers were only effective when targeted to CD22 and CD79b. In target-independent safety studies in rats, the uncleavable linker ADCs showed reduced toxicity, presumably due to the reduced release of free drug or other toxic metabolites into the circulation. Thus, our data suggest that ADCs with cleavable linkers work on a broad range of targets, and for specific targets, ADCs with uncleavable linkers provide a promising opportunity to improve the therapeutic window for ADCs in humans. [Cancer Res 2009;69(6):2358–64]

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-08-2250

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 252

Metadata

Authors
Polson, A. G., Calemine-Fenaux, J., Chan, P., Chang, W., Christensen, E., Clark, S., de Sauvage, F. J., Eaton, D., Elkins, K., Elliott, J. M., Frantz, G., Fuji, R. N., Gray, A., Harden, K., Ingle, G. S., Kljavin, N. M., Koeppen, H., Nelson, C., Prabhu, S., Raab, H., Ross, S., Stephan, J.-P., Scales, S. J., Spencer, S. D., Vandlen, R., Wranik, B., Yu, S.-F., Zheng, B., & Ebens, A.
Venue
Cancer Research
Published
2009-03-15
Volume
69
Issue
6
Pages
2358-2364
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2101893838
Cited by
252
References
36
FWCI
10.57
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antibody-Drug Conjugates for the Treatment of Non–Hodgkin's Lymphoma: Target and Linker-Drug Selection. https://app.cochat.ai/papers/10.1158/0008-5472.can-08-2250
The paper
Polson, A. G., Calemine-Fenaux, J., Chan, P., Chang, W., Christensen, E., Clark, S., de Sauvage, F. J., Eaton, D., Elkins, K., Elliott, J. M., Frantz, G., Fuji, R. N., Gray, A., Harden, K., Ingle, G. S., Kljavin, N. M., Koeppen, H., Nelson, C., Prabhu, S., . . . Ebens, A. (2009). Antibody-Drug Conjugates for the Treatment of Non–Hodgkin's Lymphoma: Target and Linker-Drug Selection. Cancer Research. https://doi.org/10.1158/0008-5472.can-08-2250

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.